Cascadian's tucatinib delays regrowth of breast cancer by a median of 7.8 months in newly updated study results presented this week.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
13F shows this mega-investor added Liberty Media and other names.
TheStreet's Adam Feuerstein answers reader questions about biotech investing.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.